William Bernat is chair of the emerging companies group and co-chair of the food and beverage group at Nutter, McClennen & Fish, LLP. Bernat offers counsel to clients navigating venture capital, private equity and angel financing matters within the food and beverage, retail and life sciences industries, with clients ranging from emerging companies to those preparing for exit.
Legal 500 Editorial commentary
Phone
617.439.2713
Email
Profile

Accolades

Boston Elite

Profile

Work Department
Corporate Department
Position

William J. Bernat is a partner in Nutter’s Corporate Department. He chairs the firm's Emerging Companies Group and co-leads the firm's Food and Beverage group. Clients routinely rely on Will to help them navigate through private equity, venture capital, and angel financing transactions, as well as mergers and acquisitions, commercial lending transactions, and other corporate governance issues.

Tech, life sciences, consumer/retail, and food & beverage companies look to Will for assistance throughout their entire lifespans, from initial planning and formation to operations and exit, including formulating the strategy to realize their business goals and to build the foundation necessary to secure third party investment. Investors in emerging growth companies seek Will’s counsel when structuring their financing transactions. Will has counseled clients in angel and venture backed financings representing an aggregate of over $500 million in investment in local early stage companies.

Banks and other financial institutions rely on Will’s expertise when structuring asset-based and other commercial lending transactions with both emerging and entrepreneurial companies and more mature borrowers. Will has guided both lenders and borrowers through transactions representing aggregate commitments in excess of $1 billion.

Content supplied by Nutter, McClennen & Fish, LLP

Work highlights

Represented RockStep Solutions, a developer of laboratory-management software for in-vivo study management in the biotechnology, pharmaceuticals, and academic sectors, in its acquisition of Instem, a global SaaS provider across discovery, study management and clinical trial analytics. The transaction created an integrated solution for preclinical research management.